MedTrace Logo

Adjuvant Quisinostat in High-Risk Uveal Melanoma

NCT06932757 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-06-03

No results posted yet for this study

Summary

The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.

Conditions

Interventions

DRUG

Quisinostat

Participants will receive 12 mg of Quisinostat via capsule to be taken orally three times per week of each 21 day cycle.

Sponsors & Collaborators

  • Viriom

    collaborator INDUSTRY

  • Joseph and Florence Mandel Family Foundation

    collaborator UNKNOWN

  • University of Miami

    lead OTHER

Principal Investigators

  • Jose Lutzky, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2030-05-27
Completion
2030-05-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932757 on ClinicalTrials.gov